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Abstract
Objective: Elevated serum IL-6 level is a risk factor for coronary heart disease (CHD). The 2174G.C and 2572G.C
polymorphisms in the IL-6 gene have previously been shown to modulate IL-6 levels. But the association between the
2174G.C and 2572G.C polymorphisms and the risk of CHD is still unclear. A meta-analysis of all eligible studies was
carried out to clarify the role of IL-6 gene polymorphisms in CHD.
Methods and Results: PubMed, EMBASE, Vip, CNKI and CBM-disc were searched for eligible articles in English and Chinese
that were published before October 2010. 27 studies involving 11580 patients with CHD and 17103 controls were included.
A meta-analysis was performed for the included articles using the RevMan 5.0 and Stata 10.0 softwares. Overall, the 2174C
allele was not significantly associated with CHD risk (ORs=1.04, 95%CI=0.98 to 1.10) when compared with the 2174G allele
in the additive model, and meta-analysis under other genetic models (dominant, recessive, CC versus GG, and GC versus GG)
also did not reveal any significant association. On the contrary, the 2572C allele was associated with a decreased risk of
CHD when compared with the 2572G allele (ORs=0.79, 95%CI=0.68 to 0.93). Furthermore, analyses under the recessive
model (ORs=0.69, 95%=0.59 to 0.80) and the allele contrast model (genotype of CC versus GG, ORs=0.49, 95%=0.35 to
0.70) yielded similar results. However, statistical significance was not found when the meta-analysis was restricted to studies
focusing on European populations, studies with large sample size, and cohort studies by using subgroup analysis.
Conclusions: The 2174G.C polymorphism in the IL-6 gene is not significantly associated with increased risks of CHD.
However, The 2572G.C polymorphism may contribute to CHD development. Future investigations with better study
design and large number of subjects are needed.
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Introduction
Coronary heart disease (CHD), including myocardial infarction
(MI), angina pectoris, and aterios sclerosis of the coronary arteries,
is still one of the leading causes of death and disability. CHD also
accounts for a huge consumption of health care resources
especially in rapidly ageing societies [1]. Though CHD’s etiology
seems to be multi-factorial and complicated, the most basic
pathogenic factor is the atherosclerosis of coronary artery.
Atherosclerosis is a chronic inflammatory response associated
with several pathophysiological reactions in the vascular wall [2–
3]. Inflammation plays a central role in the development of
atherosclerosis, and is considered to be a primary risk factor [4].
The inflammatory cytokines that are present in the arterial lesions
can mediate the various processes of plaque formation, plaque
progression and vessel thrombosis [5]. Furthermore, plasma levels
of inflammatory cytokines are also associated with atherosclerotic
risk in a variety of clinical setting [6–8]. Interleukin-6 (IL-6) is an
important pleiotropic cytokine that is produced by different cells
including adipocytes, endothelial cells, fibroblasts, myocytes, and
white blood cells [9]. IL-6 has a broad range of humoral and
cellular immune properties relating to inflammation, and is one of
the most important mediators of the inflammatory response [10–
11]. Some studies have reported that IL-6 can influence a variety
of cellular functions, such as B-cell immunoglobulin production,
T-cell cytotoxic activity, platelet reactivity, vascular smooth muscle
proliferation and endothelial cell activation [12–13]. Moreover,
IL-6 can activate the endothelium facilitating leukocytes migrate
into the vessel wall, and stimulate vascular smooth muscle cell
proliferation [14–15]. In addition, IL-6 regulates production of
adhesion molecules and induces secretion of monocyte chemotac-
tic protein, an important mediator for releasing other cytokines,
such as tumor necrosis factor-a and IL-1b, which subsequently
enhance the inflammatory reaction [12,15]. Epidemiological data
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subclinical cardiovascular diseases [16]. Recent studies have also
revealed the association between IL-6 plasma levels and
cardiovascular pathology [17–19]. Correlations have been found
between elevated circulating levels of IL-6 and an increased risk of
myocardial infarct in apparently healthy men, supporting a role of
IL 6 in the early stages of atherogenesis [20].
The circulating concentrations of IL-6 are likely to be
influenced by several environmental and genetic factors, subse-
quently affecting an individual’s susceptibility to disease [21–22].
Circulating levels of inflammatory markers have been linked to an
increased risk of atherosclerotic events [23]. Previous studies have
also shown the association between single nucleotide polymor-
phisms (SNPs) in the IL-6 gene and the plasma levels of IL-6 [24–
26]. Polymorphisms in the promoter region of the IL-6 gene may
result in inter-individual variation in transcription and expression
of the IL-6 gene [27]. Those SNPs of the IL-6 gene have been
reported to be functionally important since they influence IL-6
transcription rates [22].
Several polymorphisms in the IL-6 promoter have been
observed in healthy and unhealthy populations. Two single-
nucleotide polymorphisms, the common 2174 G.C variant [28]
and the less frequent 2572G.C allele [27], have been studied in
detail. Fishman’s study showed that the 2174 G.C and 2572
G.C polymorphisms in the IL-6 gene could increase the plasma
concentrations of IL-6 [21]. Other studies have reported that the
2174C allele was associated with higher plasma concentrations of
IL-6 [29–31]. It was also suggested that the polymorphisms can
influence the transcription and plasma levels of IL-6. However,
other studies did not find the associations between IL-6 levels and
the promoter polymorphisms [32–33]. It was reported that the
2174 G.C polymorphism was not associated with cardiovascular
death or a new myocardial infarction, whereas the 2572 G.C
polymorphism was associated with a borderline significant
increase in risk (P=0.05) in univariate analysis [34].
In summary, previous researches investigating the relationship
between the 2174G.Co r2572G.C polymorphisms and CHD
risk in different study populations have yielded varied results. In
order to clarify the role of IL-6 gene polymorphisms in CHD, we
have conducted a formal meta-analysis for all eligible studies
published before October 2010.
Methods
Identification and eligibility of relevant studies
Computer-based searches of PubMed, EMBASE, and China
National Knowledge Infrastructure (CNKI), VIP database for
Chinese Technical Periodicals (VIP), China Biological Medicine
Database (CBM-disc) were performed without restricting language
while using key words relating to CHD disease (e.g., CHD OR
CAD OR CVD OR ‘‘coronary disease’’ OR ‘‘coronary heart
disease’’ OR ‘‘coronary artery disease’’ OR ‘‘ischemic heart
disease’’ OR ‘‘cardiovascular disease’’ OR ‘‘heart disease’’) in
combination with words related to IL-6 (e.g., ‘‘interleukin 6’’ or
IL-6 or ‘‘IL 6’’ OR ‘‘interleukin-6’’ ) and polymorphism (e.g.,
polymorphism OR mutation OR genetic OR genotype OR
‘‘single nucleotide polymorphism’’). The searches included all
articles published before October 2010. In addition, the reference
lists in all relevant studies and review articles were also examined.
Only studies that evaluated the association between CHD and
the IL-6 gene polymorphisms were included. Included studies also
met the following criteria: (1) They were original studies
containing independent data, (2) the study design was case-control
study or cohort study, (3) the diagnosis of disease was definite
(Relevant clinical outcome in cases should be confirmed by WHO
criteria or coronary stenosis, which is defined variously as
minimally 50% or 70% stenosis of at least one major coronary
arteries ), (4) the 2174G.Co r2572G.C genotype frequencies
of the IL6 gene were provided, (5) the risk of CHD was evaluated,
and the odds ratio (OR) value could be calculated. The major
reasons for exclusion were (1) they were family studies, (2)
insufficient data about CHD, (3) lack of accessibility to original
articles and duplicate publications.
Data extraction
Two investigators independently reviewed all studies and
extracted the data by using a standardized form. The following
information was independently summarised from each included
study: the first author, publication date, age, gender ratio, origin of
country, source of controls, study design, ethnicity, definition of
disease in cases, numbers of cases and controls, genotyping
method, frequency and numbers for each genotype. Two
reviewers compared the results from all included studies for
accuracy and discussed any discrepancies before reaching to an
agreement. If there were still some studies that the two reviewers
failed to agree on, a third reviewer was then introduced to assess
the studies.
Statistical analysis
Deviation from Hard-Weinberg Equilibrium (HWE) was
measured by x
2-test for the control groups of each study. If the
control groups were not in HWE, sensitivity analysis or subgroup
analysis was performed to test the robustness of the findings.
Meta-analysis was performed to investigate the association
between the 2174G.C and 2572G.C polymorphisms in the
IL-6 gene and the risk of CHD. We systematically assessed the risk
of different genotypes of the 2174G.C and 2572G.C
polymorphisms in CHD under various genetic models, which
included the additive (allele G versus allele C), the recessive (CC
versus GG+GC), the dominant (GG+GC versus CC), the allele
contrast (CC versus GG) and (GC versus GG) models. The
strength of association between the 2174G.Co r2572G.C
polymorphisms and CHD risk was measured by overall odds ratios
(ORs) with 95% confidence interval (95%CI).
The homogeneity between studies was assessed using Q statistic
test [35] and Higgins I
2 [36]. When heterogeneity was not
significant (PHeterogeneity$0.1), the results were pooled using a fixed
effect model and the Mantel-Haenszel method. Otherwise, a
random-effect model and the Dersimonian and Laird method [37]
were applied. Funnel plots and Begg’s test were used to examine
the publication bias for reported associations [38]. In addition,
study design (cohort studies and case control studies), source of
control (population based and hospital based), ethnicity (Europe-
an, Asian, and others), sample size (.800, 400 to 800, and ,400),
status of Hardy-Weinberg Equilibrium (meeting or deviating) and
types of CHD end points (myocardial infarction, coronary stenosis,
mixed MI and CHD) were used as characteristics for assessment of
heterogeneity. Furthermore, subsidiary analyses including sub-
group analyses, random-effects meta-regression, and adjusted
meta-analysis were performed according to above characteristics.
All analyses were performed by using the Review-manager 5.0.1
(Oxford, England) and the Stata version 10.0 (Stata Corporation,
College Station, Texas. USA) softwares. All P-values were two-
sided.
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Characteristics of the Included Studies
A total of 486 articles were found based on the above searching
criteria. 202 overlapping articles were excluded after comparing
the title and author name. 220 articles were further excluded
including reviews, editorials, and studies with insufficient detail on
IL-6 or irrelevant outcome with CHD or MI by reading abstracts.
Detailed evaluation on the full texts of the remaining 64 articles
subsequently excluded 31 articles that failed to meet the inclusion
criteria. Further assessment excluded 6 ineligible articles because
of duplication [39,56–57,60–62]. Finally, 27 articles [32–33,40–
55,58–59,63–69] were included in the meta-analysis (Figure 1).
Summary of statistics
In the 27 included articles, a total of 11580 patients and 17103
controls were investigated. The characteristics of those studies in
the meta-analysis were listed in Table S1 and Table S2. There
were 14 studies from European countries, 11 studies from Asian
countries (8 in east Asian, 3 in south Asian), 1 study from America,
and 1 study from Brazil. The studies were case control in design,
except for two studies that were cohort studies (Table S1). Only
four studies on the 2174G.C polymorphism and no study on the
2572 G.C polymorphism reported the sex-specific polymor-
phism distribution for the IL-6 gene. The diagnoses in the
included articles were CHD, CVD, MI, AMI and CAD. All of
them were classified using WHO criteria or coronary arteriogra-
phy ($50% stenosis in at least one major artery). 24 studies used
population-based controls, and 3 studies used hospital-based
controls (Table S2). All genotypes and allele frequencies of the
2174G.C and 2572G.C polymorphisms in cases and controls
were shown in Tables S3, S4, respectively. For the 2174G.C
polymorphism, 22 studies with 28 comparisons were available,
including a total of 11060 cases and 16752 controls (Table S3). For
the 2572G.C polymorphism, 13 studies covered a total of 3255
cases and 6243 controls (Table S4). In most of the studies the
polymorphisms were found to occur in frequencies consistent with
HWE. However, statistically significant deviations from HWE
were found in four studies (two for the 2174G.C polymorphism
and two for the 2572G.C polymorphism), and HWE could not
be calculated in two other studies (Table S3, S4).
Association of the IL-6 gene 2174G.C polymorphism
with CHD risk
The association between the 2174G.C polymorphism and
CHD risk was investigated under the additive model (allele C
versus allele G). Substantial heterogeneity among the studies
(I
2=35%, P=0.036) was found. The overall OR under a random-
effects model was 1.04 (95% CI=0.98 to 1.10), and was not
significant (Figure S1). The result was stable when using the
cumulate Meta-analysis according to the publication years (Figure
S2). An overall analysis under all other genetic models was then
performed. The results of meta-analysis did not also show a
significant association under the dominant model (OR=1.05,
95%CI=0.95 to 1.16) and the recessive model (OR=1.03,
95%CI=0.95 to 1.11). Furthermore, significant association was
not found under other pair-wise comparisons (allele CC versus
GG, and allele GC versus GG). The results were shown in Table 1.
In order to analyze characteristic-homogeneous groups, sub-
group analyses were carried out according to study characteristics
including ethnicity, type of study, sample size, source of controls
and HWE status. No significant association was found under the
Figure 1. Flow diagram summarizing the search strategy for meta-analysis of IL-6 gene 2174 G.C,2572G.C and CHD.
doi:10.1371/journal.pone.0034839.g001
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mentioned above. The sensitivity analysis between the fixed model
and the random model also indicated that the changes of most
results were slight (Table 2).
Association of the IL-6 gene 2572G.C polymorphism
with CHD risk
13 studies were included in the meta-analysis of the 2572G.C
polymorphism with CHD risk. Analysis of 2572G.C polymor-
phism in the IL-6 gene with CHD risk under the additive model
was performed and the random model was used to assess the
overall OR value. Compared with the carrier of the G allele, the
overall OR of the C allele with CHD risk was 0.79 (95%CI=0.68
to 0.93) (Table 1, Figure S3). Under the recessive and the
dominant models, the overall OR was 0.69 (95%CI=0.59 to 0.80)
and 1.29 (95%CI=0.98 to 1.69), respectively. When pair-wise
comparisons were made, comparing with the GG genotype, the
overall OR of the CC genotype with CHD risk was 0.49
Table 1. ORs and 95% CI for coronary heart disease and the 2174G.C, 2572 G.C polymorphism in IL-6 gene under various
genetic models.
I
2 p-value for Statistic Effect estimate
Genetic model Comparisons Participant (%) heterogeneity model OR (95% CI)
2174 G.C polymorphism
Additive 28 53980 35 0.036 Random 1.04 (0.98, 1.10)
Recessive 28 27454 0 0.56 Fixed 1.03 (0.95, 1.11)
Dominant 28 26526 44 0.007 Random 1.05 (0.95, 1.16)
CC vs GG 28 14243 17 0.23 Fixed 1.05 (0.96, 1.15)
GC vs GG 28 21359 57 0.0002 Random 1.06 (0.94, 1.19)
2572 G.C polymorphism
Additive 13 18442 54.2 0.01 Random 0.79 (0.68, 0.93)
Recessive 13 9221 15.1 0.29 Fixed 0.69 (0.59, 0.80)
Dominant 13 9221 49.4 0.02 Random 1.29 (0.98, 1.69)
CC vs GG 13 7498 0 0.50 Fixed 0.49 (0.35, 0.70)
GC vs GG 13 7681 39 0.07 Random 0.86 (0.67, 1.11)
doi:10.1371/journal.pone.0034839.t001
Table 2. Studies of the 2174G.C polymorphism in IL-6 gene and risk of coronary heart disease under additive model grouped by
study characteristics.
Study I
2 Effect estimate Effect estimate
characteristics Comparisons Participants (%) OR (95% CI) (fixed) OR (95% CI) (random)
Over all 28 26526 35 1.03 (0.99, 1.07) 1.04 (0.98, 1.10)
Ethnicity
European 19 22128 49 1.03 (0.98, 1.08) 1.05 [0.97, 1.12]
Asian 6 2775 0 0.98 (0.85, 1.14) 0.99 [0.85, 1.14]
Other 3 1623 28 1.11 (0.95, 1.29) 1.08 [0.89, 1.32]
Type of study
Case control 25 18122 41 1.02 (0.97, 1.07) 1.03 [0.96, 1.11]
Cohort 3 8404 0 1.08 (0.97, 1.20) 1.08 [0.97, 1.20]
Sample size
Large (.800) 11 21025 2.3 1.03 (0.98, 1.08) 1.16 (0.93, 1.45)
Middle(400–800) 5 2658 24.9 0.94 (0.83, 1.06) 0.94 (0.82, 1.09)
Little(,400) 12 2843 43.9 1.20 (1.04, 1.38) 1.16 (0.93, 1.45)
Control source
Hospital 4 1117 73 1.17 (0.96, 1.42) 1.16 [0.79, 1.71]
Population 24 25409 21 1.02 (0.98, 1.07) 1.03 [0.98, 1.08]
HWE status
Meeting HWE 24 24326 17.5 1.01 (0.97, 1.06) 1.04 (0.97, 1.07)
Deviating HWE 4 2200 66.5 1.20 (1.04, 1.39) 1.23 (0.81, 1.68)
doi:10.1371/journal.pone.0034839.t002
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the G allele, significant association of the GC genotype with CHD
risk was not found and the overall OR was 0.86 (95%CI=0.67 to
1.11). Analyses under other genetic models were shown in Table 1.
According to study characteristics, the subgroup analysis and
sensitivity analysis were performed under the additive model. The
results showed that the 2572C allele in European population had
no significant effect on the risk of CHD (OR=1.02; 95%CI:0.85–
1.22), whereas this effect was reversed in Asian population
(OR=0.71; 95%CI:0.63–0.81). Subgroup analysis by sample size
suggested heterogeneous associations of the 2572G.C polymor-
phism with CHD for the 2572C allele in studies with large sample
sizes (OR=1.02, 95%CI:0.85–1.22), and a protective effect in
studies with intermediate or smaller sample size (OR=0.71, 0.72;
95%CI: 0.58–0.87, 0.61–0.84). When stratifying by HWE, results
did not change when restricted to the studies with the confirmed
HWE. A sensitivity analysis comparing the fixed and the random
models showed only minor changes in the estimates (Table 3).
Meta-regression analysis
In order to systematically assess the heterogeneity among the
studies, a regression analysis was performed by using the
univariate model for the potential sources of heterogeneity
including sample size, ethnicity, source of controls, cases
definition, mean age of cases, HWE status, genotyping method
(RFLP and other methods) and type of study. For the 2174G.C
genotype, univariate regression analysis showed that HWE status
(b coefficient=20.0169, P=0.081, I
2-residual=28.26%, adj
R
2=62.12%) was a significant source of heterogeneity among
studies (P,0.1). The other variables were not significant sources of
heterogeneity, and all P values exceed 0.1 (Table S5). For the
2572G.C genotype, univariate regression analysis showed that
sample size (b coefficient=0.1862, P=0.04, I
2-residual=40.1%,
adj-R
2=41.8%) and ethnicity (b coefficient=20.374, P=0.02,
I
2-residual=31.6%, adj-R
2=60.8%) were significant sources of
heterogeneity among studies. The other variables were not
significant sources of heterogeneity (Table S6).
In addition, we considered an adjusted meta-analysis to evaluate
the potential source of heterogeneity from: sample size, ethnicity,
type of study and HWE. For the 2174G.C polymorphism, after
adjusted for sample size, ethnicity, type of study, and HWE,
respectively, the pooled results did not change considerably
compared to the unadjusted result. The pooled OR (95%CI)
value was 0.69 (0.51 to 0.93) for the 2572G.C polymorphism
after adjustment for ethnicity, and the association between the
2572G.C polymorphism and CHD risk was not statistically
significant after adjustment for other characteristics (Table S7).
Publication bias
We used Egger’s method to access the publication bias of the
2174G.C and 2572G.C polymorphisms in the IL-6 gene and
CHD risk under the additive model. Figure 2 showed a funnel plot
in which the log value of the OR of CHD risk was plotted against
the standard error of the log of the OR in each study on the IL-6
2174G.C polymorphism and CHD. The funnel plot for the
overall results was substantially asymmetric for small studies.
Moreover, the Egger’s test for potential publication bias suggested
that there was no significant bias (t=0.5, P=0.619). Figure 3
showed the funnel plot of publication bias on the 2572G.C
polymorphism and CHD. The plot as a whole is symmetric except
for the small studies. The result of Egger’s test showed that the
publication bias was not obvious (t=21.29, P=0.215).
Discussion
Atherosclerosis and CHD may be inflammatory conditions and
IL-6 plays a key role in the inflammation process. A meta-analysis
of prospective studies showed that the IL-6 plasma levels may be
Table 3. Studies of the 2572 G.C polymorphism in IL-6 gene and risk of coronary heart disease under additive model grouped
by study characteristics.
Study I
2 Effect estimate Effect estimate
characteristics comparisons Participants (%) OR (95% CI) (fixed) OR (95% CI) (random)
Over all 13 18442 54.2 0.80 (0.72, 0.89) 0.79 (0.68, 0.93)
Ethnicity
European 4 12998 0 1.02 (0.85, 1.22) 1.02 (0.85, 1.22)
Asian 9 5444 54.2 0.71 (0.63, 0.81) 0.70 (0.59, 0.83)
Type of Study
Case control 12 13218 51.5 0.79 (0.71, 0.87) 0.77 (0.66, 0.90)
Cohort 1 5224 1.26 (0.78, 2.05) 1.26 (0.78, 2.05)
Sample size
Large (.800) 4 12998 0 1.02 (0.85, 1.22) 1.02 (0.85, 1.22)
Middle(400–800) 2 1892 31.9 0.71 (0.58, 0.87) 0.71 (0.56, 0.91)
Little(,400) 7 3552 50.3 0.72 (0.61, 0.84) 0.69 (0.55, 0.87)
Control source
Hospital 0
Population 13 18442 51.2 0.80 (0.72, 0.89) 0.79 (0.68, 0.93)
HWE status
Meeting HWE 11 16550 56.3 0.79 (0.71, 0.88) 0.81 (0.67, 0.98)
Deviating HWE 2 1892 31.9 0.75 (0.69, 0.82) 0.71 (0.68, 0.91)
doi:10.1371/journal.pone.0034839.t003
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that the 2174C and the 2572C alleles are associated with higher
serum IL-6 concentrations [30,70]. One promising hypothesis is
that the 2174G.Co r2572G.C variants of the IL-6 gene are
associated with CHD susceptibility. However, results from
previous studies on the 2174G.C polymorphism and CHD risk
were inconsistent. Some studies, such as Bennet AM [32], Basso F
[40], Lieb W [47], Nauck M [50], etc, did not find the association
between the polymorphism and risk of CHD. Other studies, such
as Jenny NS [36], Humphries SE [42], Licastro F [48], Georges JL
[51], etc, found a higher risk of CHD associated with the C-allele.
However, most of these studies were performed in Western
countries on western populations. In addition, different charac-
teristics among studies, such as ethnicity, disease diagnosis criteria,
sources of controls, sample size, can introduce heterogeneity,
making it hard to interprete the results of association studies. It
would thus be difficult to find the robust correlation between the
polymorphisms of the IL-6 gene and CHD. In order to find out
the origin of heterogeneity and to provide a better overview on the
finding of all previous studies, a meta-analysis was performed to
analyze a very large number of events.
In the meta analysis of the 2174G.C polymorphism, which
involved 27812 subjects and 22 studies with 28 comparisons,
significant association with CHD risk can not be found in overall
comparisons under all genetic models. Results from studies with
small sample size or deviating HWE are inconsistent. One
explanation may be that small sample size and deviating HWE
may cause results bias. Study characteristics, such as means age of
cases, genotyping method, study design, source of controls and
ethnicity, showed some differences in the included studies. But
most of them were not responsible for heterogeneity by subgroup
analysis, sensitivity analysis or meta-regression analysis.
Another variant of the IL-6 gene, the 2572G.C polymor-
phism, was recently reported [27] to influence IL-6 gene
transcription, thus modulating plasma or tissue levels of IL-6.
But no association between this polymorphism and CHD risk was
observed in most studies based on Western population [40–41,51–
52]. It is possible that the frequency of the 2572C allele in
Western populations is very low. The frequency of the 2572C
allele was reported to be 0.0055 in Englishman and 0.0019 in
Scotland [40,52], as compared with a frequency of 0.15 in Indian
[65] and 0.419 in China [61]. It is also possible that the small
samples do not give adequate power to detect the significant risk in
carriers. However, the association was significant in Asian
population [54–58] and the G allele was associated with increased
risk for CHD. Our meta-analysis of the 2572G.C polymorphism
and risk of CHD, which involved in 9498 subjects and 13 studies,
showed that the G allele was associated with increased risk for
CHD when compared with the C allele under additive recessive
model and the CC versus GG genetic model. In the subgroup
analysis, associations of the G allele with risk of CHD were not
found in studies focusing on European populations, cohort study
and studies with large sample size. The heterogeneity among
studies was also evident that necessitates further studies.
Overall, a modest association existed between the 572G.C
variant and CHD risk. But this association became non-significant
when the meta-analysis was restricted to studies on European
populations, studies with larger size and cohort studies. In
addition, our meta-analysis does not support an association
between the 174G.C polymorphism and CHD risk. Compared
with a previous meta-analysis [43], the present study is much
larger including almost twice as many cases as the earlier meta-
analysis. Furthermore, not only the association between the
2174G.C polymorphism and CHD risk was assessed, but the
association between the 2572G.C polymorphism and CHD was
also evaluated. Sources of heterogeneity across studies and the
possibility of publication bias were systematically explored by
using subgroup analysis, sensitivity analysis, meta-regression and
Eggers test, etc. Our results indicate an overestimation of the true
genetic association by small studies.
Several potential limitations of this meta-analysis should be
considered. First, this meta-analysis only focused on papers
published in English and Chinese. Second, not all the control
subjects were age and sex matched to cases, which was likely one
of the causes for heterogeneity. Third, the meta-regression analysis
revealed that ethnicity and sample size were the significant sources
of heterogeneity across studies on the 572G.C polymorphism and
CHD risk. Moreover, because the included studies are observa-
tional, confounding and biases might have affected the pooled
estimates. However, the advantages of this meta-analysis were also
obvious. This study was based on a large sample size of 27
included studies with 11580 cases and 17103 controls. This is twice
the sample size that had been reported in the previous meta-
Figure 2. Begg’s funnel plot with pseudo 95% confidence limit
under the additive genetic model of 2174G.C genotype. The
size of the circle is proportional to the weight of the study.
doi:10.1371/journal.pone.0034839.g002
Figure 3. Begg’s funnel plot with pseudo 95% confidence limit
under the additive genetic model of 2572G.C genotype. The
size of the circle is proportional to the weight of the study.
doi:10.1371/journal.pone.0034839.g003
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meta-analysis were assessed in detail. Third, the associations of two
variants of the IL-6 gene with risk of CHD evaluated under
different genetic models were similar.
In conclusion, the meta-analysis provides evidence that the
2174G.C polymorphism in the IL-6 gene is not significantly
associated with increased risk of CHD. A significant association
can be found between the 2572G.C polymorphism in the IL-6
gene and CHD risk, especially in Asian populations. Furthermore,
well-designed large population studies are needed to investigate
the relation of these polymorphisms and CHD.
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